Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Labuxtinib SCHEMBL14738734 | 1.00 | KIT (1.00) | KIT | |
| Labuxtinib SCHEMBL14738252 | 1.00 | KIT (1.00) | KIT | |
| Labuxtinib SCHEMBL14751407 | 1.00 | KIT (1.00) | KIT | |
| Labuxtinib SCHEMBL14739429 | 1.00 | KIT (1.00) | KIT | |
| Labuxtinib SCHEMBL20844934 | 1.00 | KIT (1.00) | KIT | |
| Labuxtinib SCHEMBL29562904 | 0.99 | KIT (0.98) | KIT | |
| Labuxtinib SCHEMBL29441810 | 0.95 | KIT (0.91) | KIT | |
| SCHEMBL14738439 | 0.92 | KIT (1.00) | KIT | |
| SCHEMBL27336503 | 0.91 | KIT (0.84) | KIT | |
| SCHEMBL14738475 | 0.91 | KIT (1.00) | KIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11744823-B2 | Pharmaceutical compositions of a selective c-kit kinase inhibitor and methods for making and using same | THIRD HARMONIC BIO, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-11744823-B2 | Pharmaceutical compositions of a selective c-kit kinase inhibitor and methods for making and using same | THIRD HARMONIC BIO, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-20220184045-A1 | PHARMACEUTICAL COMPOSITIONS OF A SELECTIVE C-KIT KINASE INHIBITOR AND METHODS FOR MAKING AND USING SAME | Calixis Inc. | 2022-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220184045-A1 | PHARMACEUTICAL COMPOSITIONS OF A SELECTIVE C-KIT KINASE INHIBITOR AND METHODS FOR MAKING AND USING SAME | KIT, PHKG1, PHKG2 | KIT 1/4885 |
| US-11744823-B2 | Pharmaceutical compositions of a selective c-kit kinase inhibitor and methods for making and using same | KIT, PHKG1, PHKG2 | KIT 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.